Douglas D. Richman,
MD
Biography
Dr. Richman is Professor of Pathology and Medicine at the University of California San Diego (UCSD)
and the Florence Seeley Riford Chair in AIDS Research. He is Director of the Center for AIDS Research at UCSD and staff physician at the VA San Diego Healthcare System.
He trained as an infectious disease physician and medical virologist at
Stanford, the NIH and Harvard before joining the faculty at UCSD in 1976.
He has focused his investigation on HIV disease and pathogenesis for the
past 20 years. His laboratory was the first to identify HIV drug
resistance. The lab joined two others in identifying latently infected CD4
cells as the obstacle to eradication of HIV with potent antiretroviral
therapy. Recently his lab described the dynamics of the neutralizing
antibody response to HIV and the rapidity of viral escape and evolution in
response to this selective pressure.
Research Summary
Current research in Dr. Richman's laboratory focuses on
the natural history and molecular pathogenesis of HIV in a cohort of
acutely infected patients. These studies include the cell mediated and
neutralizing antibody immune responses to HIV and the viral escape and
evolution in response to these. With regard to neutralization escape, we
are interested in the epitopes that elicit the neutralizing antibody
responses to autologous virus in human infections and the viral mutations
that account for escape from these responses. We are also interested in
characterizing the epitopes that elicit the too infrequent broadly
reactive neutralizing responses in some patients. We are also investigating several other virological and host determinants of HIV transmission. This information is
central for the development of an effective HIV vaccine.
In addition virologic investigations include studies of
HIV drug resistance, the pathogenetic consequences of virus replication in
anatomic compartments and viral latency. Blood plasma, latently infected
CD4 T lymphocytes, genital secretions and cerebrospinal specimens are
being obtained from patients who are well characterized clinically,
virologically and immunologically. These studies address important issues
like selective pressures on the evolution of the HIV populations in
different body compartments and pathogenesis. They also have important
clinical implications with regard to the natural history of disease and
treatment.
Dr. Richman has authored or co-authored over
500 scientific publications. He is also a co-editor of Clinical
Virology, a state of the art clinical reference book, and editor of Antiviral
Drug Resistance. |
Selected Publications
Larder B, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 243:1731-1734, 1989
Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan
J, Cheeseman S, Barringer K, Pauletti D, Shih C-K, Myers M, Griffin J.
Nevirapine resistance mutations of HIV-1 selected during therapy. J Virol
68:1660-1666, 1994
Wong JK, Günthard HF, Havlir DV, Zhang Z-Q, Haase AT,
Ignacio CC, Kwok S, Emini E, Richman DD. Reduction of HIV-1 in blood and
lymph nodes following potent antiretroviral therapy and the virologic
correlates of treatment failure. Proc Natl Acad Sci USA, 94:12574-12579,
1997
Wong JK, Hezareh M, Günthard H, Havlir DV, Ignacio CC, Spina CA,
Richman DD. Recovery of replication-competent HIV despite prolonged
suppression of plasma viremia. Science 278:1291-1294, 1997
Günthard HF,
Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD. HIV
replication and genotypic resistance in blood and lymph nodes after a year
of potent antiretroviral therapy. J Virol, 72:2422-2428, 1998
Havlir DV,
Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P,
Sommadossi J-P, Richman DD. Drug susceptibility in HIV infection after viral
rebound in patients receiving indinavir-containing regimens. JAMA
283:229-234, 2000
Little SJ, Holte S,
Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick
E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD.
Antiretroviral-drug resistance among patients recently infected with HIV.
N Engl J Med. 347:385-394, 2002
Clinical Virology, edited by Richman DD, Whitley RJ, Hayden FG.
ASM Press, Washington, 2nd Edition 1262 pp, 2002
Richman DD, Wrin TL, Little SJ, Petropoulos
CJ. Rapid evolution of the neutralizing antibody response to HIV type 1
infection. Proc Natl Acad Sci USA 100:4144-4149, 2003
Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh Brown AJ, Macaranas TR, Lym RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts longlife persistence. Proc Natl Acad Sci USA 100:4819-4824, 2003
Pillai SK, Good B, Pond SK, Wong JK, Strain MC, Richman DD, Smith DM. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 79:1734-1742, 2005
Frost SDW, Little SJ, Kosakovsky Pond SL, Chappey C, Liu Y, Wrin T, Petropoulos CJ, Richman DD. Characterization of HIV-1 envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 79:6523-6527, 2005
Frost S, Wrin T, Smith D, Kosakovsky Pond S, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos C, Little S, Richman D. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 102:18514-18519, 2005
Smith DM, Strain MC, Frost SDW, Pillai SK, Wong JK, Wrin T, Liu Y, Petropolous CJ, Daar ES, Little SJ, Richman DD. Lack of Neutralizing Antibody Response to HIV-1 Predisposes to Superinfection. Virology, 355, pp. 1-6, 2006
